Facilitating the ‘Vaccine Era’ of COVID-19 Response: ThermoGenesis to Receive U.S. Patent for Breakthrough Serological Test Reader Technology

ThermoGenesis Distributes FDA Emergency Use Authorized COVID-19 Antibody Test Kit. What Does it Mean?

ThermoGenesis Unveils Comprehensive Suite of Products and Services to Fight the Global COVID-19 Pandemic

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2020 and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov 12, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the third quarter ended September 30, 2020 … Continued

November 5, 2020

Press Releases

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2020 and Provide a Corporate Strategic Update

Conference Call to be Held on November 12, 2020 RANCHO CORDOVA, Calif., November 5, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 … Continued

November 4, 2020

Happening Now

Breaking Down ThermoGenesis’ Recent Patent for Its Breakthrough Serological Test Reader Technology

ThermoGenesis recently announced that the United States Patent and Trademark Office (USPTO) has accepted a patent application for the company’s new breakthrough lateral flow immunoassay test reader technology. What is an Antibody Lateral Flow Immunoassay Test? An antibody lateral flow immunoassay (LFIA) test is a simple diagnostic device used to confirm the presence or … Continued

Continue to News